Status:
COMPLETED
Markers for Early Detection of Prostate Cancer
Lead Sponsor:
National Cancer Institute (NCI)
Conditions:
Prostate Cancer
Eligibility:
MALE
40-75 years
Brief Summary
This study will determine whether certain gene alterations can serve as markers for early detection of prostate cancer. Prostate cancer is often diagnosed by detecting high levels of a protein called ...
Detailed Description
In the U.S., screening by prostate-specific antigen (PSA) is widespread and considered to be an effective early detection screen for prostate cancer although there are some problems associated with it...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA:
- Patients must be within 40-75 years of age.
- Patients referred for diagnostic transrectal ultrasound and prostate needle biopsy.
- Patients must be adults and capable of understanding and signing an informed consent form.
- Patients must be willing to undergo a brief prostatic massage and provide a urine and serum specimen prior to diagnostic core needle biopsy.
- EXCLUSION CRITERIA:
- Patients with active of history of other malignancy (excluding non-melanoma skin cancer).
Exclusion
Key Trial Info
Start Date :
May 1 2003
Trial Type :
OBSERVATIONAL
End Date :
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00340717
Start Date
May 1 2003
Last Update
March 4 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Madigan Army Medical Center
Tacoma, Washington, United States, 98431